Survival impact of C-Arm cone-beam computed tomography on hepatocellular carcinoma patients undergoing chemoembolization
Open Access
- 4 June 2021
- journal article
- Published by Scientific Scholar in American Journal of Interventional Radiology
Abstract
Objectives: The objectives of the study were to evaluate the use of C-arm cone-beam computed tomography (CBCT) for tumor targeting for transarterial chemoembolization (TACE) and its impact on overall survival (OS) in hepatocellular carcinoma patients. Material and Methods: Two groups were retrospectively evaluated according to the date of the first TACE session before and after C-arm CBCT installation in late 2005 (group A [n = 34], 2004–2005; group B [n = 104], 2008+). The years 2006 and 2007 were excluded to allow for the incorporation of this new imaging technology into clinical practice. The vessel selection order was recorded for all TACE sessions. Univariate and multivariate analyses were performed to assess the impact on and predictors of survival. Results: The average TACE selection order for each patient was significantly higher in group B than in group A (P < 0.0001). The median OS was significantly longer in group B (29.34 months) than in group A (19.65 months; P = 0.0088), and the difference in duration was most pronounced in patients with tumor burdens < 25% (n = 93; P = 0.0075), in whom the 3-year survival rate was 56.1% in group B and 15.3% in group A. In these 93 patients, the OS was significant longer (P = 0.018) for high (41.07 months) versus low (19.65 months) vessel selection order across both groups. In multivariate analyses, both the period in which TACE was performed (P = 0.022) and the use of C-arm CBCT (P = 0.0075) were significant predictors of improved OS. Conclusion: Use of advanced C-arm CBCT during TACE enhances the operating physician’s ability to deliver targeted, effective therapy for hepatocellular carcinoma, an aggressive approach that favorably impacts survival.Keywords
This publication has 19 references indexed in Scilit:
- Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationJournal of Hepatology, 2011
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Utility of C-arm CT in Patients with Hepatocellular Carcinoma undergoing Transhepatic Arterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2010
- Identifying Feeding Arteries During TACE of Hepatic Tumors: Comparison of C-Arm CT and Digital Subtraction AngiographyAmerican Journal of Roentgenology, 2009
- Usefulness of Cone-Beam Volume CT with Flat Panel Detectors in Conjunction with Catheter Angiography for Transcatheter Arterial EmbolizationJournal of Vascular and Interventional Radiology, 2007
- Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison of Survival Rates with Different Embolic AgentsJournal of Vascular and Interventional Radiology, 2005
- Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and SurvivalJournal of Vascular and Interventional Radiology, 2005
- Yttrium-90 microspheres for the treatment of hepatocellular carcinomaGastroenterology, 2004
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaJournal of Hepatology, 2002